开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

已收盘 01-05 15:59:36

2.120

+0.080

+3.92%

最高2.140	最低1.990	成交量240.68万
今开2.080	昨收2.040	日振幅7.35%
总市值10.58亿	流通市值10.58亿	总股本4.99亿
成交额504.89万	换手率0.48%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.12,"timestamp":1767599976250,"preClose":2.04,"halted":0,"volume":2406784,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.4023665461978104,"marketStatus":"已收盘","change":0.08,"latestTime":"01-05 15:59:36","open":2.08,"high":2.14,"low":1.99,"amount":5048932,"amplitude":0.073529,"askPrice":2.13,"askSize":325000,"bidPrice":2.12,"bidSize":14000,"shortable":0,"etf":0,"ttmEps":-0.431051611355956,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767663000000},"marketStatusCode":5,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.04,"openAndCloseTimeList":[[1767576600000,1767585600000],[1767589200000,1767600000000]],"volumeRatio":1.681128,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2601100590","title":"1月5日中源协和涨6.11%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601100590","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601100590?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:32","pubTimestamp":1767598330,"startTime":"0","endTime":"0","summary":"证券之星消息，1月5日中源协和涨6.11%，收盘报26.74元，换手率4.03%，成交量18.84万手，成交额4.93亿元。融资融券方面近5日融资净流出3316.55万，融资余额减少；融券净流出3.68万，融券余额减少。重仓中源协和的公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为5.03亿元，最新净值0.5584，较上一交易日下跌0.16%，近一年上涨13.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","159938","BK1574","BK0042","09939","BK0188","600645","BK0046","BK0216","BK1515"],"gpt_icon":0},{"id":"2601005451","title":"华昊中天医药-B盘中异动 下午盘快速下跌7.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601005451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601005451?lang=zh_cn&edition=full","pubTime":"2026-01-05 13:03","pubTimestamp":1767589415,"startTime":"0","endTime":"0","summary":"2026年01月05日下午盘13时03分，华昊中天医药-B股票出现波动，股价大幅跳水7.09%。截至发稿，该股报3.930港元/股，成交量2.32万股，换手率0.01%，振幅6.38%。华昊中天医药-B股票所在的生物技术行业中，整体涨幅为5.71%。其相关个股中，昭衍新药、圣诺医药-B、映恩生物-B涨幅较大，振幅较大的相关个股有拨康视云-B、轩竹生物-B、昭衍新药，振幅分别为19.51%、16.49%、14.03%。华昊中天医药-B公司简介：公司是一家专注于肿瘤治疗领域的创新药企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105130335953bfb4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105130335953bfb4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","09939","BK1161","02563"],"gpt_icon":0},{"id":"2601796810","title":"广州白云山医药集团股份有限公司发布2025年12月证券变动月报","url":"https://stock-news.laohu8.com/highlight/detail?id=2601796810","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601796810?lang=zh_cn&edition=full","pubTime":"2026-01-05 00:30","pubTimestamp":1767544200,"startTime":"0","endTime":"0","summary":"中访网数据广州白云山医药集团股份有限公司于2026年1月2日向香港交易及结算所有限公司提交了截至2025年12月31日的证券变动月报表。报告显示，该公司在本报告期内，其法定股本及已发行股本结构均未发生变动。在已发行股份方面，截至2025年12月31日，公司已发行股份总数与上月底结存数保持一致。A股已发行股份总数为1,405,890,949股，H股已发行股份总数为219,900,000股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105003039a49b820d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105003039a49b820d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1521","BK1606","BK1515","BK1191","00874","09939","BK1161","BK1197"],"gpt_icon":0},{"id":"2600428900","title":"周云曙履新先声药业总裁，“医药老将”回归引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2600428900","media":"医药经济报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600428900?lang=zh_cn&edition=full","pubTime":"2026-01-04 11:57","pubTimestamp":1767499065,"startTime":"0","endTime":"0","summary":"据业内消息确认，周云曙已正式履职先声药业集团总裁一职。2025年12月27日，在江苏省肿瘤医院与先声药业的战略合作签约仪式现场，周云曙首次以先声药业集团总裁的身份公开亮相。前后东家的战略对勘周云曙此次加盟的先声药业，近年来展现出强劲的发展势头。目前，先声药业正在多个领域建立优势。对于现年55岁的周云曙来说，这次职业变动不仅是个人职业生涯的转折点，也引发了医药行业的广泛关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104121307a6f081c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104121307a6f081c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","BK1161","BK1583","09939","BK1191","BK1515","BK1574","01276"],"gpt_icon":1},{"id":"2600043255","title":"2025年医药IPO市场回暖，20余家药企成功上市募资","url":"https://stock-news.laohu8.com/highlight/detail?id=2600043255","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600043255?lang=zh_cn&edition=full","pubTime":"2026-01-04 10:33","pubTimestamp":1767493992,"startTime":"0","endTime":"0","summary":"回顾刚刚过去的2025年，生物医药企业IPO活动回升，根据数据统计，2025年全年共有21家生物药企成功实现IPO。其中，药企上演赴港IPO狂欢，累计有18家公司在港交所上市，募资总额约235亿港元。港股生物医药板块于2025年迎来强力反弹，18家药企IPO。而2022年板块21家新上市企业全部破发；2023年IPO数量仅10家，募资总额约107亿港元。据悉，2025年恒瑞医药单笔募资113亿港元，创下板块IPO纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104103529a6f041a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104103529a6f041a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","HK0000252160.HKD","BK1161","HK0000500386.USD","LU2543165471.USD","BK1574","09939","01276","HK0000252152.HKD","BK1515","09606"],"gpt_icon":0},{"id":"2600145040","title":"国泰海通医药2026年1月月报：景气延续 持续重点推荐创新药械产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2600145040","media":"国泰海通证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600145040?lang=zh_cn&edition=full","pubTime":"2026-01-04 00:00","pubTimestamp":1767456000,"startTime":"0","endTime":"0","summary":"维持以下A 股标的增持评级：恒瑞医药、科伦药业、华东医药、恩华药业、特宝生物、京新药业、益方生物、药明康德、泰格医药、乐普医疗、联影医疗、微电生理，并将上述标的纳入国泰海通医药2026 年1 月月度组合。2025 年12 月上证综指上涨2.1%，SW 医药生物下跌4.1%，涨跌幅在申万一级行业中排名第26位。截至2025 年12 月底，医药板块相对于全部A 股的溢价水平目前处于正常水平，当前相对溢价率63.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104185821a49aac0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104185821a49aac0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1583","BK1515","BK1147","BK1191","BK1161","01276","03692","BK1574","BK1589","BK1564","06160","02611"],"gpt_icon":0},{"id":"2600023514","title":"国药控股与贝达药业战略合作，打造协同高效的医药供应链新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2600023514","media":"财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600023514?lang=zh_cn&edition=full","pubTime":"2026-01-04 00:00","pubTimestamp":1767456000,"startTime":"0","endTime":"0","summary":"近日，“国药控股&贝达药业战略合作签约仪式暨项目启动会”在贝达总部举行。此次国药控股与贝达药业深度携手，是“创新药企”与“供应链巨头”优势互补、强强联合的典范。面向未来，国药控股与贝达药业将持续深化合作、智联共进，携手打造协同高效的医药供应链新生态。国药控股副总裁胡立刚表示，国药控股非常高兴能与贝达药业达成战略合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104130513a6f0a2dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104130513a6f0a2dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1197","BK1161","BK1500","01099","BK1515","LU0640798160.USD","09939","LU1115378108.SGD"],"gpt_icon":0},{"id":"2600099366","title":"山西省公布第二批省级消费品特色园区名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2600099366","media":"黄河新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600099366?lang=zh_cn&edition=full","pubTime":"2026-01-03 08:19","pubTimestamp":1767399540,"startTime":"0","endTime":"0","summary":"2025年12月30日，省商务厅、省工业和信息化厅联合发布通知，公布第二批省级消费品特色园区名单。经过组织申报、专家评审、分析研判及公示等多轮严格程序，山西转型综合改革示范区医药消费品特色园区、怀仁经济技术开发区医药消费品特色园区等12个定位清晰、特色鲜明的园区入选，将进一步推动全省消费品工业集聚化、高质量发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-03/doc-inheytmt2879738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","09939","BK1161","BK1574"],"gpt_icon":0},{"id":"2600575062","title":"每周股票复盘：华兰股份（301093）设立AI医药专家委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=2600575062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600575062?lang=zh_cn&edition=full","pubTime":"2026-01-03 01:53","pubTimestamp":1767376389,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，华兰股份报收于51.1元，较上周的48.57元上涨5.21%。本周，华兰股份12月31日盘中最高价报51.27元。华兰股份当前最新总市值83.91亿元，在医疗器械板块市值排名43/127，在两市A股市值排名2228/5181。本周关注点公司公告汇总：华兰股份设立AI医药专家委员会，旨在为董事会战略与投资委员会提供决策建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1515","BK1574","159938","301093","09939"],"gpt_icon":0},{"id":"2600057076","title":"2025年医药领域十位“失意者”的退场悲歌与行业之变","url":"https://stock-news.laohu8.com/highlight/detail?id=2600057076","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600057076?lang=zh_cn&edition=full","pubTime":"2026-01-02 18:03","pubTimestamp":1767348229,"startTime":"0","endTime":"0","summary":"有人在创新风口上起舞，也有人在亏损泥潭中沉没……在刚刚过去的2025年，国内医药行业被政策调控、资本退潮与研发内卷三重绞杀，一轮史无前例的残酷洗牌全面上演。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601023607593644.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601023607593644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1574","09939","BK1161","159938"],"gpt_icon":0},{"id":"2600435096","title":"开拓药业-B01月02日主力净流入62.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2600435096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600435096?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:15","pubTimestamp":1767341748,"startTime":"0","endTime":"0","summary":"01月02日, 开拓药业-B股价涨4.08%，报收2.04元，成交金额253.1万元，换手率0.25%，振幅5.10%，量比0.98。开拓药业-B今日主力资金净流入62.2万元，上一交易日主力净流出0万元。该股近5个交易日上涨6.25%，主力资金累计净流入178.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出191.2万元，其中净流出天数为6日。该股主力净额占比0.06%，港股市场排名91/2707。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102161843a6eb201e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102161843a6eb201e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2600036476","title":"每周股票复盘：中恒集团（600252）拟清算医药投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036476?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:18","pubTimestamp":1767295092,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，中恒集团报收于2.78元，较上周的2.89元下跌3.81%。公司公告汇总广西梧州中恒集团股份有限公司第十届董事会第三十五次会议于2025年12月29日召开，审议通过关于清算注销广西力合中恒医药投资合伙企业的议案，同意依法进行清算并注销该合伙企业。广西梧州中恒集团股份有限公司2025年第三次临时股东大会于2025年12月29日召开，审议通过取消监事会并修订公司章程、续聘2025年度会计师事务所、提名第十届董事会董事候选人等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0012","BK1515","BK0015","BK0188","BK0239","BK0077","159938","BK0028","600252","09939","BK1161"],"gpt_icon":0},{"id":"2595793337","title":"港股拿下2025年IPO募资榜全球第一，医药板块成为“顶梁柱”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595793337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595793337?lang=zh_cn&edition=full","pubTime":"2025-12-31 20:01","pubTimestamp":1767182504,"startTime":"0","endTime":"0","summary":"值得一提的是，据港交所数据，2025年香港新股IPO市场融资额位居全球第一，累计募资总额突破2800亿港元。其中，恒瑞医药以113.74亿港元位列2025年港股IPO企业募资额前五。与此同时，今年8月4日起，香港交易所正式实施IPO分配机制新规。智通财经APP了解到，2022年至2024年，港股IPO破发率一直稳定在32%-34%，但在2025年，在IPO企业数量更多的情况下，这一比率反降至28.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2595772344","title":"第4次“圈地运动”！国药再砸122亿，上药、华润扩“内需”，流通巨头新活法？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772344","media":"E药经理人","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595772344?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:18","pubTimestamp":1767176329,"startTime":"0","endTime":"0","summary":"2025年，四大“巨无霸”一边对外并购，一边对内整合。据商务部最新报告，2024年前五大流通“巨无霸”收入加起来约为13363亿元，同比增长仅0.6%，2023年同比增长为9.6%。国药今年先后完成两笔重要交易。荐阅读* 国药再下滑、九州通猛追，上药、华润守位，流通巨头业绩PK中的冲刺与对垒…*国药、上药、华润、九州通，5家千亿巨头就位！今年8月，华润医药商业增资浙江震元全资子公司震元医药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231185024a48e4dea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231185024a48e4dea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01099","02607","09939","BK1574","LU1115378108.SGD","BK1500","BK1515","BK1161","LU0640798160.USD","BK1197"],"gpt_icon":0},{"id":"2595778040","title":"森萱医药（920946）披露召开2026年第一次临时股东会通知公告，12月31日股价上涨0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778040?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:14","pubTimestamp":1767176056,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，森萱医药报收于10.55元，较前一交易日上涨0.19%，最新总市值为45.04亿元。该股当日开盘10.55元，最高10.65元，最低10.45元，成交额达2058.17万元，换手率为0.46%。近日，江苏森萱医药股份有限公司发布公告，宣布将于2026年1月15日召开2026年第一次临时股东会，会议将采用现场投票与网络投票相结合的方式进行。股权登记日为2026年1月12日，本次会议将审议《关于预计2026年度日常关联交易的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100034064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"2595720337","title":"华兰股份最新公告：设立AI医药专家委员会并选举委员","url":"https://stock-news.laohu8.com/highlight/detail?id=2595720337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595720337?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:34","pubTimestamp":1767173656,"startTime":"0","endTime":"0","summary":"华兰股份(301093.SZ)公告称，公司董事会同意在董事会战略与投资委员会下设AI医药专家委员会，由3名委员组成，其中主任委员1名。委员会将为公司AI医药相关业务提供全局性战略规划与技术指导，构建产学研协同创新生态，并链接世界顶尖专家资源和国际客户资源。此外，公司选举LIU JUN（刘军）先生、孙茂松先生、赵宏先生担任AI医药专家委员会委员，其中LIU JUN（刘军）先生担任主任委员。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100031411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK1515","09939","301093","159938","BK0239"],"gpt_icon":0},{"id":"2595778845","title":"A股医药板块的“火热”与“寒意”｜记“医”2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778845","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778845?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:27","pubTimestamp":1767173277,"startTime":"0","endTime":"0","summary":"2025年，随着“至暗时刻”过去，A股医药板块呈现出结构性分化的特征：一方面，创新药和CXO板块凭借海外需求和BD（BusinessDevelopment，即商业拓展）出海“热火朝天”；另一方面，中药、医疗器械、医药商业等板块业绩承压，仍感受“寒意”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512313607060327.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512313607060327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","09939","BK1574","BK1161","159982","BK1515","399300"],"gpt_icon":0},{"id":"2600770809","title":"每日卖空追踪 | 同源康医药-B 12月31日卖空量成交5500股，卖空比例为0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600770809","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600770809?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:30","pubTimestamp":1767169830,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间12月31日，跌0.61%，卖空量成交5500股，较上一交易日减少84.72%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163428a48dc78e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231163428a48dc78e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1515","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2600701559","title":"医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701559","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600701559?lang=zh_cn&edition=full","pubTime":"2025-12-31 07:00","pubTimestamp":1767135600,"startTime":"0","endTime":"0","summary":"在生物医药行业里，中国已经成为创新的重要力量。而在创新队列中，恒瑞作为龙头企业，始终占据着重要位置。恒瑞医药董事长孙飘扬在2025年研发日上表示，恒瑞始终坚持创新与国际化战略。通过“借船出海”与“自主出海”等多元路径，恒瑞正加速推动创新产品走向全球，致力于成长为一家真正的全球化制药企业。这些数据表明中国创新药正从“跟随式创新”迈向“全球领跑”的新阶段。一举创下国内史上BD单笔交易规模最大纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231081832a6e30a98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231081832a6e30a98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0359201612.USD","BK1574","LU0359202008.SGD","BK1515","09939","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","BK1191","01276"],"gpt_icon":0},{"id":"2595754742","title":"亿腾医药，成功借壳嘉和生物，视作重新上市、今早正式生效，并更名为亿腾嘉和","url":"https://stock-news.laohu8.com/highlight/detail?id=2595754742","media":"瑞恩资本Ryanbe...","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595754742?lang=zh_cn&edition=full","pubTime":"2025-12-30 21:09","pubTimestamp":1767100179,"startTime":"0","endTime":"0","summary":"肿瘤及自体免疫药物的开发商嘉和生物药业于周二发布公告，与生物制药公司亿腾医药集团自2024年9月推进合并，后者通过反方向形式收购或借壳，视作重新上市，已于今早正式生效，并正式易名为亿腾嘉和，成为在香港首家生物医药或科技公司完成借壳合并的交易。是次嘉和生物药业合并的生物制药公司亿腾医药集团，面向抗感染、心血管及呼吸系统疾病等，从事原研药收购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230220549a6e1ab29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230220549a6e1ab29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1161","09939","BK1583","06998"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0625},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.184},{"period":"6month","weight":0.36},{"period":"1year","weight":1.125},{"period":"ytd","weight":0.0408}],"compareEarnings":[{"period":"1week","weight":0.0201},{"period":"1month","weight":0.0224},{"period":"3month","weight":-0.0296},{"period":"6month","weight":0.1013},{"period":"1year","weight":0.3422},{"period":"ytd","weight":0.0276}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.04604},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}